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Abstract
Purpose. To implement an evidence-based hyperlipidemia guideline for statin therapy use with
diabetic patients. Background. In the United States, cardiovascular disease (CVD) continues to
be the leading cause of mortality and morbidity for women and men with diabetes. Dyslipidemia
is a modifiable risk factor for CVD and one of the leading drivers behind the development of
coronary artery disease. In 2014, the American Diabetes Association issued a new
recommendation guideline for using statins as a primary intervention for CVD in patients aged
40–75 with diabetes. Despite advances in prevention and treatment guidelines, the American
College of Cardiology and ADA have identified a substantial gap in hyperlipidemia guideline
implementation across clinical settings. Methods. Patients with diabetes were identified and
assigned a statin dose based on their risk factors for atherosclerotic CVD. Patients with a history
of clinical atherosclerotic CVD were initiated on a high-dose statin therapy, whereas those with
no history of CVD were initiated on a moderate-dose statin therapy. Follow-up was conducted at
6 weeks. Outcomes. Out of 122 diabetic patients, 61 (46.5%) were newly started on a statin, 33
(27%) had their statin corrected to the proper dose, 28 (23%) were on the proper statin dose
already, and 8 (3.5%) were ineligible for a statin. All patients (100%) taking a statin tolerated
their dose and experienced no adverse effects. Implications for Practice. Bridging the gap
between research and practice can be successful with careful implementation of a system that
can be followed to improve outcomes.
Keywords: diabetes, cardiovascular disease, statin therapy.
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Diabetes mellitus (hereafter referred to as diabetes) is a chronic health condition that
occurs when the body produces little to no insulin. Diabetes develops from a combination of
genetic and environmental factors (Martín-Timón, Sevillano-Collantes, Segura-Galindo, & Del
Cañizo-Gómez, 2014). An estimated 366 million people worldwide were reported to have
diabetes in 2011, although half were undiagnosed; the total figure is expected to rise to 552
million by 2030 (Martín-Timón et al., 2014). Approximately 25.8 million people in the United
States are living with diabetes (Thapa et al., 2015). As the prevalence of the disease increases, so
will the proportion of older adults (i.e., ≥ 65 years) with the condition (Thapa et al., 2015).
Diabetes is a well-established risk factor for cardiovascular disease (CVD). Compared with
individuals without diabetes, patients with Type 2 diabetes are twice as likely to suffer from
cardiovascular morbidity and mortality and are disproportionately affected by CVD. The Centers
for Disease Control and Prevention (2017) reported that CVD is the leading cause of death for
men and women with diabetes.
In 2013, the American College of Cardiology (ACC) and American Heart Association
jointly issued a new recommendation for treatment using 3-hydroxy-3-methylglutaryl-coenzyme,
a reductase inhibitor otherwise known as a statin, as primary prevention of atherosclerotic CVD
for people with diabetes between 40 and 75 years old. The 2017 American Diabetes Association
(ADA) guidelines for statin therapy are as follows (see Appendix A for details): 1) individuals
age 40 and younger: no statin recommendation; 2) patients aged 40–75 with diabetes and no risk
factors for atherosclerotic CVD: moderate statin therapy in addition to lifestyle modifications; 3)
patients aged 40–75 with diabetes and risk factors for atherosclerotic CVD: moderate or highintensity statin therapy in addition to lifestyle modifications (ADA, 2017). Lifestyle
modifications include weight management; reducing consumption of saturated fat, trans fats, and
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cholesterol; increasing dietary intake of omega-3 fatty acids and viscous fiber; and increased
activity. These lifestyle changes can help improve lipid profiles in diabetic patients.
Apart from lifestyle changes, statins have been identified as the most effective first-line
drugs for lowering cholesterol and reducing cardiovascular risk (Page, Sanfilippo, Geelhoed,
Briffa, & Hobbs, 2012). The Food and Drug Administration has approved several types of
statins, each of which works differently to lower cholesterol by blocking the liver’s production of
HMG CoA enzyme used in making cholesterol. Commonly prescribed statins include Lovastatin
(Mevacor), Atorvastatin (Lipitor), Simvastatin (Zocor), Pravastatin (Livalo), Fluvastatin
(Lescol), and Rosuvastatin (Crestor); see Appendix B for dosage information.
Statement of the Problem
Several clinical studies have demonstrated the benefits of statin therapy in the primary
and secondary prevention of atherosclerotic CVD and even death in diabetic patients. The ADA
(2017) conducted a meta-analysis of data from 18,000 patients with diabetes based on 14
randomized trials of statin therapy. Results showed that the all-cause mortality rate declined by
9% and the vascular mortality rate declined by 13% when LDL cholesterol was reduced by
39mg/dL. According to Kiramijyan et al. (2013), the most common cause of death in diabetic
patients is coronary artery disease; approximately 70% of diabetic patients die of CVD and are
twice as likely to suffer from related conditions including myocardial infarction, angina pectoris,
stroke, and cardiac death compared to the general population. Of individuals living with diabetes
in the U.S., 735,000 have had a heart attack (525,000 first-time episodes and 210,000 recurrent)
(CDC, 2017). Modifiable risk factors for CVD include hypertension, dyslipidemia, and obesity;
non-modifiable risk factors include diabetes, age, ethnicity, and family history of heart disease.
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Background and Significance
Research has led to the adaptation and implementation of recommended hyperlipidemia
guidelines in the use of statin therapy in diabetic patients. Studies have shown that statin therapy
substantially reduces the risk of a future cardiovascular event in patients with Type 2 diabetes
regardless of their history of heart disease. The initiation of statin therapy is primarily based on
risk factors rather than cholesterol levels. Page et al. (2012) reported that approximately 5,355
major cardiovascular events, including 1,456 fatal events, could have been prevented in diabetes
patients aged 60–79 if statin therapy had been initiated. Thapa et al. (2015) noted significant
improvements in lipid management and fewer cardiovascular events in diabetic patients given
statin therapy. Thapa et al. (2015) also found that healthcare providers tended to underutilize
guidelines regarding the use of statin therapy to all diabetic patients irrespective of CVD
diagnosis; specifically, healthcare providers were more likely to provide statin therapy to
diabetes patients with CVD than to those without.
Pokharel et al. (2016) reported that some healthcare providers manage diabetic patients
and CVD differently from those without CVD even though both groups have the same risk
factors. Hence, a gap remains between current recommendation guidelines in statin use and their
implementation in clinical practice. National efforts to adopt guidelines for the use of statin
therapy in all diabetic patients must therefore be intensified. Pokharel et al. (2016) urged
healthcare providers and patients to discuss prevention strategies related to heart attack, stroke,
and other risk factors at every opportunity. Eliminating barriers, such as inadequate medical
records, and creating decision support tools (e.g., alerts and reminders, clinical guidelines, and
focused patient data report dashboards) may help improve recommended guidelines on statin use
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to enhance risk reduction along with clinical performance and patient outcomes (Pokharel et al.,
2016).
Assessment
The site for this research project was a small, independently owned family practice clinic
in Kingwood, TX. Dr. A. J. is a primary care/family medicine doctor and owns the clinic with
her spouse, a nephrologist. Dr. A. J. completed her medical education in India and has been
practicing for 32 years. The clinic accepts patients from ages 16 to 65 and older. The youngest
patient at the clinic is 16, and the oldest is 93. Major patient categories are presented in Table 1;
patient ethnicities are listed in Table 2. With regard to education level, patients hold a high
school diploma on average. Some Hispanic patients speak little to no English.
The clinic is approximately 2,000 square feet and includes a waiting room, three triage
rooms, two physician offices, one staff lounge/break room, a secretarial space, and a small staff
workstation. The clinic accepts all types of insurance as well as uninsured and self-pay patients.
Approximately 10 to 25 patients are seen in the clinic per day (10–15 current patients and 5–10
new). The clinic sees 30 to 50 current patients per week (100–150/month) and 20 to 25 new
patients (30–50/month) within the same time frame. The clinic provides primary care, preventive
services, and acute illness and chronic disease management. The clinic staff includes a physician,
a secretary, and a medical assistant who also acts as the office manager. Dr. J.A.’s husband, a
nephrologist, co-owns the practice and has scheduled appointments throughout the week during
which he sees patients with acute or chronic kidney diseases. Patients are required to schedule an
appointment before coming to see a physician. The clinic staff also requires that appointments be
made to discuss abnormal lab or diagnostic results and for follow-up visits. The secretary is the
only bilingual staff member and serves as an interpreter for the clinic’s non-English-speaking
Hispanic population.
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Table 1
Clinic Population in 2017
Patient
status

# of patients

Established

4,100

62

New

2,525

38

Diabetics

1,720

26

Diabetics
with h/o
CVD
and/or
HLD

1,235

19

Percent (%)
(N = 6,625)

Table 2
Ethnicities of Clinic Patients
# of patients
Ethnicity
(%)
Non-Hispanic
whites
African
American

40
20

Hispanic/Latino

30

Other

10

Organization’s Readiness for Change
The clinic provides high-quality care to its patient population as reported in patient
satisfaction surveys (average score of 4.4 out of 5). Patients were reportedly satisfied with Dr. A.
J.’s care. They generally felt their diagnoses and medications were properly managed and
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reported positive post-treatment health outcomes. However, recent guidelines regarding the
recommendation of statin therapy to all diabetic patients with or without a history of
atherosclerotic CVD is not being implemented at the clinic. According to the ACC (2016), two
out of five individuals with diabetes could benefit from statin therapy in lowering their risk for a
cardiovascular event, as patients with Type 2 diabetes are at high risk for atherosclerotic CVD
and stroke (ADA, 2017). These patients are also considered to be at equal risk of a future
cardiovascular event as individuals with a history of CVD (Thapa et al., 2015). Therefore, it is
important to control CVD risk factors such as elevated cholesterol levels.
Routine screening for atherosclerotic CVD risk and providing patient education around
prevention are similarly important (ADA, 2017). Effective counseling and medication-based
education can help patients understand their increased risks of atherosclerotic CVD and high
LDL cholesterol levels. Such measures may help to improve patient outcomes at the clinic.
Optimal care of patients with Type 2 diabetes depends on providers and the quality of care they
offer patients, especially regarding prevention of future cardiovascular events and, by extension,
high morbidity and mortality (ADA, 2017). As noted, the ADA guideline around the
recommended use of statin therapy was not being implemented with all diabetic patients
(especially those with no history of CVD) at Dr. A. J.’s practice. The clinic also had no
electronic medical record alert system through which to provide guideline reminders. Upon
meeting with Dr. A. J. and discussing the ADA’s recommended clinical guideline, the clinic
appeared ready to adopt a change in practice.
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Project Identification
Purpose
The purpose of this project is to initiate an evidence-based quality improvement project
concerning the implementation of an ADA hyperlipidemia treatment guideline for the use of
statin therapy on diabetic patients.
Objectives
1. To implement the APA’s hyperlipidemia clinical guideline.
2. To educate the physician and clinic staff of the guideline and scope of the DNP project.
3. By April 2018, 100% of identified diabetic patients in Dr. A. J.’s clinic will be educated
about and given appropriate supplementary material on the benefits of statin therapy.
4. By April 2018, at least 90% of diabetic patients in Dr. A. J.’s clinic will begin statin
therapy and adhere to the treatment guideline.
Anticipated Outcomes
1. 100% of the physician and clinic staff will be educated on the hyperlipidemia guideline
2. 100% of the clinic’s diabetic patients will be educated on the guideline.
3. 90% of patients will begin statin therapy and be monitored appropriately.
Summary and Strength of the Evidence
According to the U.S. Preventive Service Task Force (2016), coronary artery disease is
responsible for about one-fifth of deaths in adults aged 45–65 and one-fourth of deaths in adults
aged 65 and older. The benefits of statin use in reducing CVD-related morbidity and mortality
have been demonstrated in several studies (USPSTF, 2016). A study of 19 randomized trials
totaling 71,344 participants evaluated the effects of statin use in adults with diabetes with no
history of CVD events; results showed statin use to be statistically associated with a reduced
incidence of CVD, myocardial infarction, and stroke (USPSTF, 2016). A primary prevention
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trial on statin use, JUPITER, found that statin allocation was associated with a 39% reduction in
major CVD events such as heart attack or ischemia, a 36% reduction in venous
thromboembolism, a 17% reduction in total mortality, and avoidance of 134 vascular events or
deaths (Ridker, Pradhan, MacFadyen, Libby, & Glynn, 2012). The JUPITER primary prevention
trial concluded that the benefits of statin therapy exceeded the risks associated with diabetes and
CVD (Ridker et al., 2012).
Method
Project Intervention
The setting of the project was Dr. A. J.’s family care clinic, a small, independently owned
family practice located in southeastern TX. A statin therapy guideline was implemented in all
diabetic patients between 40 and 75 years old. Data collected from patients’ electronic medical
records (EMRs) included demographic information such as age, gender, ethnicity, insurance
type, education level, current medications, and medical history and laboratory test results (see
Appendix B). The physician and clinic staff were instructed on the evidence-based
hyperlipidemia clinical guideline on statin use before implementing it. They were also educated
on the algorithm (Appendix D) that explained the steps and assigned roles of each staff. The
algorithm was posted by each computer in the nurses’ station for reference. Educational
brochures were created to help familiarize the patient population with the benefits of using statin
therapy and its relationship with cardiovascular risk factors. The clinic’s secretary, who is also a
medical assistant, served as a Spanish interpreter to educate non-English-speaking diabetic
patients and their caregivers.
When patients called for an appointment, the secretary verified whether they were
diabetic; if so, these patients’ appointment times were coded in blue, and their EMRs were
flagged once statin therapy was initiated to ensure appropriate evaluation of their treatment plan.
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On the day of patients’ appointments, during the triage process, the medical assistant verified
their medication to determine whether patients were on a statin therapy and documented each
patient’s response under the Assessment tab in his/her EMR. Patients with diabetes were also
given a brochure educating them on the benefits of statin therapy. The physician assessed
patients by reviewing their lab tests at baseline to verify whether they were eligible to receive a
statin, ensure they were assigned the correct dose, and began statin therapy with an emphasis on
adhering to the treatment guideline. Each patient’s liver function test was reviewed at baseline
and monitored during a 4-week follow-up plan. The statin was dosed based on the patient’s
atherosclerotic CVD risk. Patients with a history of clinical atherosclerotic CVD were initiated
on a high-dose statin therapy, whereas those with no history of CVD were initiated on a
moderate-dose statin therapy. Dr. A. J. conducted follow-up appointments at 4 weeks.
Organizational Barriers
Hispanics comprised approximately 50% of the clinic’s diabetic patient population.
African Americans constituted about 40%, and the remaining 10% was a mix of other races.
Most Hispanic patients spoke little to no English and were often accompanied by a family
member to translate. Although the clinic’s medical assistant interpreted for Spanish-speaking
clientele, this could be viewed as a barrier because her primary role was overseeing the front
office. She therefore managed various tasks, such as answering phone calls, scheduling
appointments, verifying insurance, sending appointment reminders, and checking patients in and
out. Being called into a triage room to interpret for a patient could be disruptive when other tasks
required equal attention. The clinic is actively looking to hire an additional bilingual staff
member to assist its Spanish-speaking population. The clinic’s insufficient staff posed another
barrier; considering that the two staff members (i.e., medical assistant and secretary) were
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overburdened with responsibilities, continued implementation of this clinical guideline could
eventually be overlooked.
Staff time may also present a barrier to ongoing implementation of this project. Although
the clinical practice is small, time constraints due to understaffing could lead to tasks remaining
unfinished, such as following up on appointments, referrals, and laboratory/diagnostic results.
Staff rarely clock out on time, often staying 30 minutes to an hour after their shift to complete
outstanding work. Another potential barrier is the average education level of the patient
population (i.e., high school) and corresponding eighth grade comprehension in many cases. In
addition, no written or verbal medication education was being given to patients, yet medication
information and counseling are essential parts of patient care and should be provided during
patient–provider interaction at each visit office visit (Yi et al., 2015). To promote effective
medication compliance, providers must tailor education to each patients’ needs, level of
understanding, and preferred format (e.g., verbal, written, or both) (Yi et al., 2015).
The use of unskilled staff may further explain why continued patient compliance to
medication regimens could pose an organizational barrier. The clinic is staffed with two medical
assistants with a high school education; educating patients about medications is beyond their
scope of practice, as is monitoring patients’ lab values and medication adherence. According to
Barra (2011), a medical assistant lacks the educational and clinical background that a nurse
possesses from years of education and continuous practice; thus, medical assistants are generally
unprepared to adequately interpret lab results and educate patients about their medications. Barra
(2011) emphasized that patient safety and well-being can be at risk when there is a lack of
competent, licensed staff to render high-quality patient services.
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A lack of contact time between provider and patients was another barrier to effective
continuation of this project. Dr. A. J.’s family care practice is a prime example of a fast-paced
healthcare system; it is a small, busy clinic with only one provider, and effective patient
monitoring can be easily overlooked when trying to move through patients quickly. According to
Yi et al., (2015), brief contact between healthcare providers and patient is a barrier to effective
medication adherence. Continued compliance with statin therapy could therefore prove
challenging, as patients required substantial reinforcement during each office visit to ensure
ongoing adherence to the statin regimen.
Facilitators
The physician and staff voiced their willingness to assist with and support the
implementation of the ADA’s hyperlipidemia clinical guideline. The student (i.e., project
researcher) was equally hopeful about the project. A hyperlipidemia guideline is urgently needed
and should prove beneficial to all patients with diabetes. The clinic’s EHR system also allowed
patients’ records to be color-coded and flagged for simple patient identification, which facilitated
follow-up for the duration of the project.
Ethical Implications
No ethical concerns were anticipated regarding the implementation of the hyperlipidemia
guideline.
Results
A total of 149 diabetic patients visited Dr. A. J.’s clinic from January 21, 2018 to April 6,
2018; see Table 3 for patient characteristics and corresponding data. Appendix C outlines the
patient data collected each week. The DNP student reviewed each patient’s EMR weekly to
ensure the hyperlipidemia guideline was followed. Patients’ pre-intervention satisfaction scores
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revealed that 80% of patients believed that their diagnoses and medications were not being well
managed at the clinic. In addition, they did not feel that their health outcomes had improved. The
remaining 20% felt that their diagnoses and medications were properly managed by the
physician. Patient satisfaction scores after guideline implementation demonstrated a substantial
increase; see Table 4. Patients also reported positive health outcomes. Clinic staff now routinely
conducts follow-up assessments.
Table 3
Patient Data Analysis
Patient
characteristics
Already on
statin

Total
(N = 149)

Percentage
(%)

61

41

Not on statin

88

50

8

5

80

54

28

19

33

22

0

0

88

50

113

76

Ineligible for
statin
(contraindicated)
Eligible for
statin
Proper statin
dose
Improper statin
dose
Developed side
effects
Nutritional
consult provided
Brochure
provided
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Table 4
Patient Satisfaction Scores
Pre (%)

Post (%)

Not
satisfied

80

5

Satisfied

20

95

Discussion
The purpose of this project was to implement the ADA’s hyperlipidemia clinical
guideline on initiating statin therapy to diabetic patients regardless of their lipid level, with or
without a history of CVD. Diabetes is a risk factor for CVD, which places diabetics at risk of
cardiovascular events. Despite the benefits of statin therapy, studies have indicated that
recommended treatment guidelines are often not upheld in clinical practice. Busko (2016)
conducted a comparative study to examine statin regimens among 215,193 diabetic patients
between 40 and 75 years old. She discovered that only 62% of diabetic patients were prescribed
a statin or being monitored by a cardiologist for CVD-related issues when they received a statin
prescription. Busko (2016) further noted that statin prescription varied widely among practices;
two out of five diabetic patients without CVD were not prescribed a statin. Healthcare providers
who manage diabetic patients should ensure these patients are receiving preventive therapies, of
which statins are one of the most important (Busko, 2016).
One noteworthy change over the course of this project was an increase in patient
satisfaction scores. Patients reported that the care they received was of high quality, safe, and
effective. They felt much more satisfied with their care and believed that the clinic genuinely
cared about their health and well-being. A major contributing factor to the success of this project
was the clinic staff’s willingness to implement the recommended guideline. They worked
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effectively to ensure that each of their assigned project roles was fulfilled despite managing an
already overwhelming workload. Staff initially struggled to complete their assigned roles, but the
additional duties eventually became a part of their daily routine. Another point of success in this
project was the lack of patient refusal; every patient participated and complied with guideline
implementation. Educational brochures, careful explanation of the guideline, and patient
education on the benefits of statin use aided in their compliance. The clinic’s EMR system also
facilitated project completion. The clinic’s staff was able to easily implement the statin initiation
and monitoring process because they could readily identify the diabetic population via the EMR
system.
Limitations
A limitation encountered during this project was some patients’ failure to attend their
follow-up appointments. A 4-week follow up appointment was scheduled for each patient to
monitor and evaluate liver function lab results; however, approximately 35% of patients did not
keep their appointments. The clinic staff thus had to spend time placing appointment reminder
calls and rescheduling missed appointments.
Recommendations
Knowledge deficits were prevalent in patients not on statin therapy at the start of this
project. Approximately 90% of diabetic patients assessed at the clinic stated they had no
knowledge of the guideline. As a recommendation, healthcare providers should strive to
coordinate an ongoing diabetes self-management education class for all diabetic patients. Such
education would help to enhance patients’ awareness and skills related to optimal self-care.
Patients could also incorporate their personal needs and life experiences to make informed
decisions as they face new challenges while managing diabetes. The hyperlipidemia guideline
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also recommends lifestyle modifications as a complement to statin therapy. At the clinic, half of
diabetic patients received a nutritional consult; in the future, all patients should be provided
individualized medical nutritional therapy with a dietician. Nutrition-specific instructions will
enable diabetic patients to maintain good glycemic control, lipid control, and evaluate how well
they respond to therapy.
Implications for Practice
Management of diabetic patients can be complex and involves several components
(Richardson, Derouin, Vorderstrasse, Hipkens, & Thompson, 2014). The prevalence of diabetes
is expected to triple by 2050, and many regions may see a sharp increase in diabetic patients as a
result (Richardson et al., 2014). Many healthcare organizations are under pressure to apply
innovative interventions and identify cost-effective approaches to treat this population
(Richardson et al., 2014). Healthcare organizations have begun to integrate nurse practitioners
(NPs) as internists to assist in improving clinical outcomes for diabetic patients, namely through
NPs’ willingness to initiate, change, and adjust medications and offer patients alternate modes of
treatment (Richardson et al., 2014). Especially in primary care settings, NPs have been shown to
increase quality of care while reducing healthcare costs and improving health outcomes. In
addition, NPs can use evidence-based clinical metrics to make immediate changes to patients’
treatment regimens when patients are not improving as anticipated (Richardson et al., 2014).
The Doctor of Nursing Practice (DNP) Essential II, “Scientific Underpinnings for
Practice,” calls for organizational and systems leadership for quality improvement (American
Association of Colleges of Nursing, 2006). DNPs contribute to nursing science by evaluating,
translating, and disseminating research into practice (American Association of Colleges of
Nursing, 2006). Key skills include the development of clinical practice guidelines, design of
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evidence-based interventions, and evaluation of practice outcomes. Being able to lead and
manage change within the healthcare environment is one of the most important roles of a DNP
nurse (Stichler, 2011). DNP nurse leaders possess the skills and competencies to lead and guide
staff members within healthcare organizations through the change process by using a thoughtful
and deliberate approach to help ensure adoption and maintenance of change over time (Stichler,
2011).
This project followed the DNP essentials as described in Essential II by first undertaking
a leadership role in identifying a patient safety issue at the clinic. A quality improvement plan
was developed using an evidence-based clinical guideline to resolve the issue. Overall, the DNP
student assumed a leadership role in ensuring appropriate implementation of the project. These
contributions elicited positive change in the clinic’s operations that should continue into the
future.
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Appendix A
Table A1
Statin Therapy Indications and Intensity for Patients with Diabetes
Risk factor
History of atherosclerotic
CVD
CVD risk factor

No risk factor

Age

Statin intensity

All age groups

High

40–75
75 and older
40 and younger

Moderate or high
High
None

40–75
75 and older

Moderate
Moderate or high
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Table A2
ADA Treatment Recommendations for Different Statins

Atorvastatin

Recommended
daily dose (adult;
mg)
10–80

Low
intensity
(mg)
10–20

Moderate
intensity
(mg)
20–40

High
intensity
(mg)
40–80

Rosuvastatin

5–40

5

10–20

20–40

Fluvastatin

20–40

40–80

Pravastatin

20–80
Immediate release
10–80
Extended release
10–60
10–40

10–20

40–80

Simvastatin

5–80

5–10

20–40

Statin

Lovastatin

80
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Appendix B
Table B1
Patient Demographic Data
Characteristics

Number of patients
(N = 149)

Percentage (%)
(N = 149)

Age
40–55
56–65
66–75

61
38
50

41
26
33

Gender
Female
Male

64
85

43
57

Ethnicity
Caucasian
African American
Hispanic
Asian

28
52
48
21

19
35
32
14

Insurance
Insured
Uninsured

104
45

70
30

Education
Less than high school
High school
Some college
College graduate
Masters degree and over

26
49
23
37
14

17
33
15
25
9
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Appendix C
Table C1
Weekly Assessment Data Spreadsheet

On
statin
(n = 61)

Not on
statin
(n =
80)

On improper
statin dose
(n = 33)

On proper
statin dose
(n = 28)

13

4

9

2

2

Total
placed
on
statin
(n =
113)
11

Wk. 2

11

4

7

3

1

10

0

Wk. 3
Wk. 4
Wk. 5
Wk. 6
Wk. 7
Wk. 8
Wk. 9
Wk. 10

15
18
12
19
16
18
11
16

7
9
5
10
4
8
4
6

8
9
7
9
12
10
7
10

4
3
4
6
2
4
1
4

2
4
1
2
2
2
3
2

11
10
11
13
14
12
8
9

1
2
0
2
0
2
0
1

Week

Diabetic
patients
at clinic
(N = 149)

Wk. 1

Ineligible
for statin
(n = 8)
0
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Appendix D

Secretary
Ask new Pt if
DM
Color code the
chart in EMR
blue
Pt's EMR will be
flagged once
statin is initiated

Figure 1. Algorithm.

MA
Get Pt’s med list
Ask if on statin
Doc on
assessment for
MD to review
Provide Pt with
educational
material

MD
Evaluate Pt
Review lab
results
Decide whether
Pt receives statin
Follow-up plan

